BioSyent Inc. (TSXV:RX)

Market Cap	127.95M
Revenue (ttm)	35.03M
Net Income (ttm)	7.27M
Shares Out	11.26M
EPS (ttm)	0.62
PE Ratio	18.44
Forward PE	14.02
Dividend	0.20 (1.76%)
Ex-Dividend Date	Feb 28, 2025

Volume	7,789
Average Volume	3,522
Open	11.30
Previous Close	11.30
Day's Range	11.25 - 11.36
52-Week Range	8.24 - 12.13
Beta	0.85
RSI	62.41
Earnings Date	Mar 14, 2025

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2024, BioSyent's revenue was 35.03 million, an increase of 10.89% compared to the previous year's 31.59 million. Earnings were 7.27 million, an increase of 12.54%.